Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers

The present study reports the case of a 70-year-old Caucasian man who was referred to the Military Hospital of Buenos Aires for evaluation of a giant sellar-extrasellar mass with extension in the right temporal lobe and compression of the third ventricle. Patient was initially responsive to cabergol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Publicado:	2009
Materias:	Dopamine agonist resistance FGF IGFI Ki67 Prolactinoma VEGF cabergoline CD31 antigen fibroblast growth factor 2 growth hormone Ki 67 antigen octreotide somatomedin C vasculotropin antineoplastic agent ergoline derivative prolactin tumor marker aged amnesia article attention disturbance brain third ventricle cancer invasion case report drug dose increase fatality gait disorder growth hormone release headache human immunohistochemistry male priority journal prolactinoma sleep disorder temporal lobe tumor growth tumor vascularization visual impairment blood drug resistance genetics hypophysis tumor hypothyroidism metabolism neovascularization (pathology) nuclear magnetic resonance imaging pathology Aged Antineoplastic Agents Drug Resistance, Neoplasm Ergolines Humans Hypothyroidism Immunohistochemistry Magnetic Resonance Imaging Male Neovascularization, Pathologic Pituitary Neoplasms Prolactin Tumor Markers, Biological
Acceso en línea:	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10463976_v20_n1_p35_MalleaGil http://hdl.handle.net/20.500.12110/paper_10463976_v20_n1_p35_MalleaGil
Aporte de:	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

id	paper:paper_10463976_v20_n1_p35_MalleaGil
record_format	dspace
spelling	paper:paper_10463976_v20_n1_p35_MalleaGil2023-06-08T16:01:12Z Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers Dopamine agonist resistance FGF IGFI Ki67 Prolactinoma VEGF cabergoline CD31 antigen fibroblast growth factor 2 growth hormone Ki 67 antigen octreotide somatomedin C vasculotropin antineoplastic agent cabergoline ergoline derivative prolactin tumor marker aged amnesia article attention disturbance brain third ventricle cancer invasion case report drug dose increase fatality gait disorder growth hormone release headache human immunohistochemistry male priority journal prolactinoma sleep disorder temporal lobe tumor growth tumor vascularization visual impairment blood drug resistance genetics hypophysis tumor hypothyroidism metabolism neovascularization (pathology) nuclear magnetic resonance imaging pathology prolactinoma Aged Antineoplastic Agents Drug Resistance, Neoplasm Ergolines Humans Hypothyroidism Immunohistochemistry Magnetic Resonance Imaging Male Neovascularization, Pathologic Pituitary Neoplasms Prolactin Prolactinoma Tumor Markers, Biological The present study reports the case of a 70-year-old Caucasian man who was referred to the Military Hospital of Buenos Aires for evaluation of a giant sellar-extrasellar mass with extension in the right temporal lobe and compression of the third ventricle. Patient was initially responsive to cabergoline with reduction of prolactin levels and shrinkage of tumor burden for at least 36 months. Thereafter, prolactin levels and tumor size increased even though cabergoline dosage was increased. Transcraneal surgery was performed at 56 months of treatment. Prolactin levels and tumor proliferation did not subside and the patient died 14 months later. High GH and IGF-I levels were observed in the late stages of tumor development, with no evidence of acromegalic features. Immunohisto-chemistry of the excised tumor revealed strong immunore-activity for VEGF and FGF-2, two potent angiogenic factors, and CD31 (an endothelial marker) indicating high vascularization of the adenoma. © Humana Press Inc. 2009. 2009 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10463976_v20_n1_p35_MalleaGil http://hdl.handle.net/20.500.12110/paper_10463976_v20_n1_p35_MalleaGil
institution	Universidad de Buenos Aires
institution_str	I-28
repository_str	R-134
collection	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic	Dopamine agonist resistance FGF IGFI Ki67 Prolactinoma VEGF cabergoline CD31 antigen fibroblast growth factor 2 growth hormone Ki 67 antigen octreotide somatomedin C vasculotropin antineoplastic agent cabergoline ergoline derivative prolactin tumor marker aged amnesia article attention disturbance brain third ventricle cancer invasion case report drug dose increase fatality gait disorder growth hormone release headache human immunohistochemistry male priority journal prolactinoma sleep disorder temporal lobe tumor growth tumor vascularization visual impairment blood drug resistance genetics hypophysis tumor hypothyroidism metabolism neovascularization (pathology) nuclear magnetic resonance imaging pathology prolactinoma Aged Antineoplastic Agents Drug Resistance, Neoplasm Ergolines Humans Hypothyroidism Immunohistochemistry Magnetic Resonance Imaging Male Neovascularization, Pathologic Pituitary Neoplasms Prolactin Prolactinoma Tumor Markers, Biological
spellingShingle	Dopamine agonist resistance FGF IGFI Ki67 Prolactinoma VEGF cabergoline CD31 antigen fibroblast growth factor 2 growth hormone Ki 67 antigen octreotide somatomedin C vasculotropin antineoplastic agent cabergoline ergoline derivative prolactin tumor marker aged amnesia article attention disturbance brain third ventricle cancer invasion case report drug dose increase fatality gait disorder growth hormone release headache human immunohistochemistry male priority journal prolactinoma sleep disorder temporal lobe tumor growth tumor vascularization visual impairment blood drug resistance genetics hypophysis tumor hypothyroidism metabolism neovascularization (pathology) nuclear magnetic resonance imaging pathology prolactinoma Aged Antineoplastic Agents Drug Resistance, Neoplasm Ergolines Humans Hypothyroidism Immunohistochemistry Magnetic Resonance Imaging Male Neovascularization, Pathologic Pituitary Neoplasms Prolactin Prolactinoma Tumor Markers, Biological Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers
topic_facet	Dopamine agonist resistance FGF IGFI Ki67 Prolactinoma VEGF cabergoline CD31 antigen fibroblast growth factor 2 growth hormone Ki 67 antigen octreotide somatomedin C vasculotropin antineoplastic agent cabergoline ergoline derivative prolactin tumor marker aged amnesia article attention disturbance brain third ventricle cancer invasion case report drug dose increase fatality gait disorder growth hormone release headache human immunohistochemistry male priority journal prolactinoma sleep disorder temporal lobe tumor growth tumor vascularization visual impairment blood drug resistance genetics hypophysis tumor hypothyroidism metabolism neovascularization (pathology) nuclear magnetic resonance imaging pathology prolactinoma Aged Antineoplastic Agents Drug Resistance, Neoplasm Ergolines Humans Hypothyroidism Immunohistochemistry Magnetic Resonance Imaging Male Neovascularization, Pathologic Pituitary Neoplasms Prolactin Prolactinoma Tumor Markers, Biological
description	The present study reports the case of a 70-year-old Caucasian man who was referred to the Military Hospital of Buenos Aires for evaluation of a giant sellar-extrasellar mass with extension in the right temporal lobe and compression of the third ventricle. Patient was initially responsive to cabergoline with reduction of prolactin levels and shrinkage of tumor burden for at least 36 months. Thereafter, prolactin levels and tumor size increased even though cabergoline dosage was increased. Transcraneal surgery was performed at 56 months of treatment. Prolactin levels and tumor proliferation did not subside and the patient died 14 months later. High GH and IGF-I levels were observed in the late stages of tumor development, with no evidence of acromegalic features. Immunohisto-chemistry of the excised tumor revealed strong immunore-activity for VEGF and FGF-2, two potent angiogenic factors, and CD31 (an endothelial marker) indicating high vascularization of the adenoma. © Humana Press Inc. 2009.
title	Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers
title_short	Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers
title_full	Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers
title_fullStr	Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers
title_full_unstemmed	Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers
title_sort	invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers
publishDate	2009
url	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10463976_v20_n1_p35_MalleaGil http://hdl.handle.net/20.500.12110/paper_10463976_v20_n1_p35_MalleaGil
_version_	1768543478586802176

Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers

Ejemplares similares